Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Receives Consensus Recommendation of “Buy” from Analysts

Shares of Aclaris Therapeutics, Inc. (NASDAQ:ACRS) have received an average recommendation of “Buy” from the eight analysts that are currently covering the stock, MarketBeat reports. Six research analysts have rated the stock with a buy recommendation and two have assigned a strong buy recommendation to the company. The average twelve-month price objective among brokers that have issued ratings on the stock in the last year is $11.67.

A number of equities research analysts have issued reports on the stock. Jefferies Financial Group raised shares of Aclaris Therapeutics from a “hold” rating to a “buy” rating and increased their price objective for the company from $2.00 to $7.00 in a report on Tuesday, November 19th. BTIG Research raised shares of Aclaris Therapeutics from a “neutral” rating to a “buy” rating and set a $8.00 price objective for the company in a report on Tuesday, November 19th. Leerink Partners raised shares of Aclaris Therapeutics from a “market perform” rating to an “outperform” rating and increased their price objective for the company from $2.00 to $7.00 in a report on Tuesday, November 19th. Leerink Partnrs raised shares of Aclaris Therapeutics from a “hold” rating to a “strong-buy” rating in a report on Tuesday, November 19th. Finally, Piper Sandler raised shares of Aclaris Therapeutics from a “neutral” rating to an “overweight” rating and raised their target price for the company from $3.00 to $13.00 in a report on Monday, November 18th.

Aclaris Therapeutics Price Performance

Shares of ACRS opened at $1.66 on Tuesday. Aclaris Therapeutics has a 1 year low of $0.95 and a 1 year high of $5.17. The company has a 50 day simple moving average of $2.33 and a two-hundred day simple moving average of $2.19. The firm has a market cap of $179.15 million, a P/E ratio of -3.19 and a beta of 0.48.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of ACRS. ExodusPoint Capital Management LP bought a new stake in Aclaris Therapeutics in the fourth quarter worth $26,000. Invesco Ltd. bought a new stake in Aclaris Therapeutics in the fourth quarter worth $28,000. Graham Capital Management L.P. bought a new stake in Aclaris Therapeutics in the fourth quarter worth $35,000. Commonwealth Equity Services LLC bought a new stake in Aclaris Therapeutics in the fourth quarter worth $36,000. Finally, Alpine Global Management LLC bought a new stake in Aclaris Therapeutics in the fourth quarter worth $38,000. 98.34% of the stock is owned by hedge funds and other institutional investors.

Aclaris Therapeutics Company Profile

Aclaris Therapeutics, Inc a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases.